APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Vitamin K Antagonists (VKA)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Vitamin K Antagonists (VKA) Market Outlook and Growth Opportunities 2026

Report ID 174046970420 December 2025198 pages

Choose your research edition.

Industry ResearchVitamin K Antagonists (VKA) Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Vitamin K Antagonists (VKA) Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Vitamin K Antagonists (VKA) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vitamin K Antagonists (VKA) Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Vitamin K Antagonists (VKA) Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Vitamin K Antagonists (VKA) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Vitamin K Antagonists (VKA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vitamin K Antagonists (VKA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vitamin K Antagonists (VKA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Vitamin K Antagonists (VKA) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Vitamin K Antagonists (VKA) market include Sanofi, Johnson & Johnson, Lilly, Pfizer, Bayer, AstraZeneca, The Medicines Company, Otsuka and Genentech (Roche), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vitamin K Antagonists (VKA) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vitamin K Antagonists (VKA) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vitamin K Antagonists (VKA) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vitamin K Antagonists (VKA) market size, projected growth trends, production technologies, key applications, and end-use industries.

Vitamin K Antagonists (VKA) Segment by Company

Sanofi

Johnson & Johnson

Lilly

Pfizer

Bayer

AstraZeneca

The Medicines Company

Otsuka

Genentech (Roche)

Daiichi Sankyo

Bristol-Myers Squibb

Boehringer Ingelheim

Aspen

Vitamin K Antagonists (VKA) Segment by Type

Oral Vitamin K Antagonists

Injection Vitamin K Antagonists

Vitamin K Antagonists (VKA) Segment by Application

AF

ACS/MI

VTE

Others

Vitamin K Antagonists (VKA) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Vitamin K Antagonists (VKA) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Vitamin K Antagonists (VKA) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Vitamin K Antagonists (VKA) significant trends, drivers, influence factors in global and regions.

6. To analyze Vitamin K Antagonists (VKA) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vitamin K Antagonists (VKA) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vitamin K Antagonists (VKA) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vitamin K Antagonists (VKA).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vitamin K Antagonists (VKA) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vitamin K Antagonists (VKA) industry.

Chapter 3: Detailed analysis of Vitamin K Antagonists (VKA) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Vitamin K Antagonists (VKA) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Vitamin K Antagonists (VKA) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Vitamin K Antagonists (VKA) Industry Trends Table 2. Vitamin K Antagonists (VKA) Industry Drivers Table 3. Vitamin K Antagonists (VKA) Industry Opportunities and Challenges Table 4. Vitamin K Antagonists (VKA) Industry Restraints Table 5. Global Vitamin K Antagonists (VKA) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Vitamin K Antagonists (VKA) Revenue Share by Company (2021-2026) Table 7. Global Vitamin K Antagonists (VKA) Sales Volume by Company (W Tons) & (2021-2026) Table 8. Global Vitamin K Antagonists (VKA) Sales Volume Share by Company (2021-2026) Table 9. Global Vitamin K Antagonists (VKA) Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Vitamin K Antagonists (VKA) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Vitamin K Antagonists (VKA) Key Company Manufacturing Base & Headquarters Table 12. Global Vitamin K Antagonists (VKA) Company, Product Type & Application Table 13. Global Vitamin K Antagonists (VKA) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Vitamin K Antagonists (VKA) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oral Vitamin K Antagonists Table 18. Significant Companies of Injection Vitamin K Antagonists Table 19. Global Vitamin K Antagonists (VKA) Sales Volume by Type 2021 VS 2025 VS 2032 (W Tons) Table 20. Global Vitamin K Antagonists (VKA) Sales Volume by Type (2021-2026) & (W Tons) Table 21. Global Vitamin K Antagonists (VKA) Sales Volume by Type (2027-2032) & (W Tons) Table 22. Global Vitamin K Antagonists (VKA) Sales Volume Share by Type (2021-2026) Table 23. Global Vitamin K Antagonists (VKA) Sales Volume Share by Type (2027-2032) Table 24. Global Vitamin K Antagonists (VKA) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Vitamin K Antagonists (VKA) Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Vitamin K Antagonists (VKA) Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Vitamin K Antagonists (VKA) Sales Value Share by Type (2021-2026) Table 28. Global Vitamin K Antagonists (VKA) Sales Value Share by Type (2027-2032) Table 29. Significant Companies of AF Table 30. Significant Companies of ACS/MI Table 31. Significant Companies of VTE Table 32. Significant Companies of Others Table 33. Global Vitamin K Antagonists (VKA) Sales Volume by Application 2021 VS 2025 VS 2032 (W Tons) Table 34. Global Vitamin K Antagonists (VKA) Sales Volume by Application (2021-2026) & (W Tons) Table 35. Global Vitamin K Antagonists (VKA) Sales Volume by Application (2027-2032) & (W Tons) Table 36. Global Vitamin K Antagonists (VKA) Sales Volume Share by Application (2021-2026) Table 37. Global Vitamin K Antagonists (VKA) Sales Volume Share by Application (2027-2032) Table 38. Global Vitamin K Antagonists (VKA) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Vitamin K Antagonists (VKA) Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Vitamin K Antagonists (VKA) Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Vitamin K Antagonists (VKA) Sales Value Share by Application (2021-2026) Table 42. Global Vitamin K Antagonists (VKA) Sales Value Share by Application (2027-2032) Table 43. Global Vitamin K Antagonists (VKA) Sales by Region: 2021 VS 2025 VS 2032 (W Tons) Table 44. Global Vitamin K Antagonists (VKA) Sales by Region (2021-2026) & (W Tons) Table 45. Global Vitamin K Antagonists (VKA) Sales Market Share by Region (2021-2026) Table 46. Global Vitamin K Antagonists (VKA) Sales by Region (2027-2032) & (W Tons) Table 47. Global Vitamin K Antagonists (VKA) Sales Market Share by Region (2027-2032) Table 48. Global Vitamin K Antagonists (VKA) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Vitamin K Antagonists (VKA) Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Vitamin K Antagonists (VKA) Sales Value Share by Region (2021-2026) Table 51. Global Vitamin K Antagonists (VKA) Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Vitamin K Antagonists (VKA) Sales Value Share by Region (2027-2032) Table 53. Global Vitamin K Antagonists (VKA) Market Average Price (US$/Ton) by Region (2021-2026) Table 54. Global Vitamin K Antagonists (VKA) Market Average Price (US$/Ton) by Region (2027-2032) Table 55. Global Vitamin K Antagonists (VKA) Sales by Country: 2021 VS 2025 VS 2032 (W Tons) Table 56. Global Vitamin K Antagonists (VKA) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Vitamin K Antagonists (VKA) Sales by Country (2021-2026) & (W Tons) Table 58. Global Vitamin K Antagonists (VKA) Sales Market Share by Country (2021-2026) Table 59. Global Vitamin K Antagonists (VKA) Sales by Country (2027-2032) & (W Tons) Table 60. Global Vitamin K Antagonists (VKA) Sales Market Share by Country (2027-2032) Table 61. Global Vitamin K Antagonists (VKA) Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Vitamin K Antagonists (VKA) Sales Value Market Share by Country (2021-2026) Table 63. Global Vitamin K Antagonists (VKA) Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Vitamin K Antagonists (VKA) Sales Value Market Share by Country (2027-2032) Table 65. Sanofi Company Information Table 66. Sanofi Business Overview Table 67. Sanofi Vitamin K Antagonists (VKA) Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 68. Sanofi Vitamin K Antagonists (VKA) Product Portfolio Table 69. Sanofi Recent Development Table 70. Johnson & Johnson Company Information Table 71. Johnson & Johnson Business Overview Table 72. Johnson & Johnson Vitamin K Antagonists (VKA) Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 73. Johnson & Johnson Vitamin K Antagonists (VKA) Product Portfolio Table 74. Johnson & Johnson Recent Development Table 75. Lilly Company Information Table 76. Lilly Business Overview Table 77. Lilly Vitamin K Antagonists (VKA) Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 78. Lilly Vitamin K Antagonists (VKA) Product Portfolio Table 79. Lilly Recent Development Table 80. Pfizer Company Information Table 81. Pfizer Business Overview Table 82. Pfizer Vitamin K Antagonists (VKA) Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 83. Pfizer Vitamin K Antagonists (VKA) Product Portfolio Table 84. Pfizer Recent Development Table 85. Bayer Company Information Table 86. Bayer Business Overview Table 87. Bayer Vitamin K Antagonists (VKA) Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 88. Bayer Vitamin K Antagonists (VKA) Product Portfolio Table 89. Bayer Recent Development Table 90. AstraZeneca Company Information Table 91. AstraZeneca Business Overview Table 92. AstraZeneca Vitamin K Antagonists (VKA) Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 93. AstraZeneca Vitamin K Antagonists (VKA) Product Portfolio Table 94. AstraZeneca Recent Development Table 95. The Medicines Company Company Information Table 96. The Medicines Company Business Overview Table 97. The Medicines Company Vitamin K Antagonists (VKA) Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 98. The Medicines Company Vitamin K Antagonists (VKA) Product Portfolio Table 99. The Medicines Company Recent Development Table 100. Otsuka Company Information Table 101. Otsuka Business Overview Table 102. Otsuka Vitamin K Antagonists (VKA) Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 103. Otsuka Vitamin K Antagonists (VKA) Product Portfolio Table 104. Otsuka Recent Development Table 105. Genentech (Roche) Company Information Table 106. Genentech (Roche) Business Overview Table 107. Genentech (Roche) Vitamin K Antagonists (VKA) Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 108. Genentech (Roche) Vitamin K Antagonists (VKA) Product Portfolio Table 109. Genentech (Roche) Recent Development Table 110. Daiichi Sankyo Company Information Table 111. Daiichi Sankyo Business Overview Table 112. Daiichi Sankyo Vitamin K Antagonists (VKA) Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 113. Daiichi Sankyo Vitamin K Antagonists (VKA) Product Portfolio Table 114. Daiichi Sankyo Recent Development Table 115. Bristol-Myers Squibb Company Information Table 116. Bristol-Myers Squibb Business Overview Table 117. Bristol-Myers Squibb Vitamin K Antagonists (VKA) Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 118. Bristol-Myers Squibb Vitamin K Antagonists (VKA) Product Portfolio Table 119. Bristol-Myers Squibb Recent Development Table 120. Boehringer Ingelheim Company Information Table 121. Boehringer Ingelheim Business Overview Table 122. Boehringer Ingelheim Vitamin K Antagonists (VKA) Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 123. Boehringer Ingelheim Vitamin K Antagonists (VKA) Product Portfolio Table 124. Boehringer Ingelheim Recent Development Table 125. Aspen Company Information Table 126. Aspen Business Overview Table 127. Aspen Vitamin K Antagonists (VKA) Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 128. Aspen Vitamin K Antagonists (VKA) Product Portfolio Table 129. Aspen Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Vitamin K Antagonists (VKA) Distributors List Table 133. Vitamin K Antagonists (VKA) Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Vitamin K Antagonists (VKA) Product Image Figure 2. Global Vitamin K Antagonists (VKA) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vitamin K Antagonists (VKA) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Vitamin K Antagonists (VKA) Sales (2021-2032) & (W Tons) Figure 5. Global Vitamin K Antagonists (VKA) Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Vitamin K Antagonists (VKA) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oral Vitamin K Antagonists Image Figure 10. Injection Vitamin K Antagonists Image Figure 11. Global Vitamin K Antagonists (VKA) Sales Volume by Type (2021 VS 2025 VS 2032) & (W Tons) Figure 12. Global Vitamin K Antagonists (VKA) Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Vitamin K Antagonists (VKA) Sales Volume Share by Type (2021-2032) Figure 14. Global Vitamin K Antagonists (VKA) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Vitamin K Antagonists (VKA) Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Vitamin K Antagonists (VKA) Sales Value Share by Type (2021-2032) Figure 17. AF Image Figure 18. ACS/MI Image Figure 19. VTE Image Figure 20. Others Image Figure 21. Global Vitamin K Antagonists (VKA) Sales Volume by Application (2021 VS 2025 VS 2032) & (W Tons) Figure 22. Global Vitamin K Antagonists (VKA) Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Vitamin K Antagonists (VKA) Sales Volume Share by Application (2021-2032) Figure 24. Global Vitamin K Antagonists (VKA) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Vitamin K Antagonists (VKA) Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Vitamin K Antagonists (VKA) Sales Value Share by Application (2021-2032) Figure 27. Global Vitamin K Antagonists (VKA) Sales by Region: 2021 VS 2025 VS 2032 (W Tons) Figure 28. Global Vitamin K Antagonists (VKA) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Vitamin K Antagonists (VKA) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Vitamin K Antagonists (VKA) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Vitamin K Antagonists (VKA) Sales Value (2021-2032) & (US$ Million) Figure 32. North America Vitamin K Antagonists (VKA) Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Vitamin K Antagonists (VKA) Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Vitamin K Antagonists (VKA) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Vitamin K Antagonists (VKA) Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Vitamin K Antagonists (VKA) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Vitamin K Antagonists (VKA) Sales Value (2021-2032) & (US$ Million) Figure 38. South America Vitamin K Antagonists (VKA) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Vitamin K Antagonists (VKA) Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Vitamin K Antagonists (VKA) Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Vitamin K Antagonists (VKA) Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Vitamin K Antagonists (VKA) Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Vitamin K Antagonists
  • Injection Vitamin K Antagonists
Applications
  • AF
  • ACS/MI
  • VTE
  • Others
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Lilly
  • Pfizer
  • Bayer
  • AstraZeneca
  • The Medicines Company
  • Otsuka
  • Genentech (Roche)
  • Daiichi Sankyo
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Aspen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vitamin K Antagonists (VKA) Sales Value (2021-2032)
  4. 1.2.2 Global Vitamin K Antagonists (VKA) Sales Volume (2021-2032)
  5. 1.2.3 Global Vitamin K Antagonists (VKA) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Vitamin K Antagonists (VKA) Market Dynamics
  1. 2.1 Vitamin K Antagonists (VKA) Industry Trends
  2. 2.2 Vitamin K Antagonists (VKA) Industry Drivers
  3. 2.3 Vitamin K Antagonists (VKA) Industry Opportunities and Challenges
  4. 2.4 Vitamin K Antagonists (VKA) Industry Restraints
3 Vitamin K Antagonists (VKA) Market by Company
  1. 3.1 Global Vitamin K Antagonists (VKA) Company Revenue Ranking in 2025
  2. 3.2 Global Vitamin K Antagonists (VKA) Revenue by Company (2021-2026)
  3. 3.3 Global Vitamin K Antagonists (VKA) Sales Volume by Company (2021-2026)
  4. 3.4 Global Vitamin K Antagonists (VKA) Average Price by Company (2021-2026)
  5. 3.5 Global Vitamin K Antagonists (VKA) Company Ranking (2024-2026)
  6. 3.6 Global Vitamin K Antagonists (VKA) Company Manufacturing Base and Headquarters
  7. 3.7 Global Vitamin K Antagonists (VKA) Company Product Type and Application
  8. 3.8 Global Vitamin K Antagonists (VKA) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Vitamin K Antagonists (VKA) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Vitamin K Antagonists (VKA) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Vitamin K Antagonists (VKA) Market by Type
  1. 4.1 Vitamin K Antagonists (VKA) Type Introduction
  2. 4.1.1 Oral Vitamin K Antagonists
  3. 4.1.2 Injection Vitamin K Antagonists
  4. 4.2 Global Vitamin K Antagonists (VKA) Sales Volume by Type
  5. 4.2.1 Global Vitamin K Antagonists (VKA) Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Vitamin K Antagonists (VKA) Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Vitamin K Antagonists (VKA) Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Vitamin K Antagonists (VKA) Sales Value by Type
  9. 4.3.1 Global Vitamin K Antagonists (VKA) Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Vitamin K Antagonists (VKA) Sales Value by Type (2021-2032)
  11. 4.3.3 Global Vitamin K Antagonists (VKA) Sales Value Share by Type (2021-2032)
5 Vitamin K Antagonists (VKA) Market by Application
  1. 5.1 Vitamin K Antagonists (VKA) Application Introduction
  2. 5.1.1 AF
  3. 5.1.2 ACS/MI
  4. 5.1.3 VTE
  5. 5.1.4 Others
  6. 5.2 Global Vitamin K Antagonists (VKA) Sales Volume by Application
  7. 5.2.1 Global Vitamin K Antagonists (VKA) Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Vitamin K Antagonists (VKA) Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Vitamin K Antagonists (VKA) Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Vitamin K Antagonists (VKA) Sales Value by Application
  11. 5.3.1 Global Vitamin K Antagonists (VKA) Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Vitamin K Antagonists (VKA) Sales Value by Application (2021-2032)
  13. 5.3.3 Global Vitamin K Antagonists (VKA) Sales Value Share by Application (2021-2032)
6 Vitamin K Antagonists (VKA) Regional Sales and Value Analysis
  1. 6.1 Global Vitamin K Antagonists (VKA) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vitamin K Antagonists (VKA) Sales by Region (2021-2032)
  3. 6.2.1 Global Vitamin K Antagonists (VKA) Sales by Region: 2021-2026
  4. 6.2.2 Global Vitamin K Antagonists (VKA) Sales by Region (2027-2032)
  5. 6.3 Global Vitamin K Antagonists (VKA) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Vitamin K Antagonists (VKA) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Vitamin K Antagonists (VKA) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Vitamin K Antagonists (VKA) Sales Value by Region (2027-2032)
  9. 6.5 Global Vitamin K Antagonists (VKA) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Vitamin K Antagonists (VKA) Sales Value (2021-2032)
  12. 6.6.2 North America Vitamin K Antagonists (VKA) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Vitamin K Antagonists (VKA) Sales Value (2021-2032)
  15. 6.7.2 Europe Vitamin K Antagonists (VKA) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Vitamin K Antagonists (VKA) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Vitamin K Antagonists (VKA) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Vitamin K Antagonists (VKA) Sales Value (2021-2032)
  21. 6.9.2 South America Vitamin K Antagonists (VKA) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Vitamin K Antagonists (VKA) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Vitamin K Antagonists (VKA) Sales Value Share by Country, 2025 VS 2032
7 Vitamin K Antagonists (VKA) Country-level Sales and Value Analysis
  1. 7.1 Global Vitamin K Antagonists (VKA) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Vitamin K Antagonists (VKA) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Vitamin K Antagonists (VKA) Sales by Country (2021-2032)
  4. 7.3.1 Global Vitamin K Antagonists (VKA) Sales by Country (2021-2026)
  5. 7.3.2 Global Vitamin K Antagonists (VKA) Sales by Country (2027-2032)
  6. 7.4 Global Vitamin K Antagonists (VKA) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Vitamin K Antagonists (VKA) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Vitamin K Antagonists (VKA) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Vitamin K Antagonists (VKA) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Vitamin K Antagonists (VKA) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Vitamin K Antagonists (VKA) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Vitamin K Antagonists (VKA) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Vitamin K Antagonists (VKA) Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Vitamin K Antagonists (VKA) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Vitamin K Antagonists (VKA) Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Lilly
  14. 8.3.1 Lilly Company Information
  15. 8.3.2 Lilly Business Overview
  16. 8.3.3 Lilly Vitamin K Antagonists (VKA) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Lilly Vitamin K Antagonists (VKA) Product Portfolio
  18. 8.3.5 Lilly Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Vitamin K Antagonists (VKA) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Vitamin K Antagonists (VKA) Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Bayer
  26. 8.5.1 Bayer Company Information
  27. 8.5.2 Bayer Business Overview
  28. 8.5.3 Bayer Vitamin K Antagonists (VKA) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bayer Vitamin K Antagonists (VKA) Product Portfolio
  30. 8.5.5 Bayer Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Vitamin K Antagonists (VKA) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Vitamin K Antagonists (VKA) Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 The Medicines Company
  38. 8.7.1 The Medicines Company Company Information
  39. 8.7.2 The Medicines Company Business Overview
  40. 8.7.3 The Medicines Company Vitamin K Antagonists (VKA) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 The Medicines Company Vitamin K Antagonists (VKA) Product Portfolio
  42. 8.7.5 The Medicines Company Recent Developments
  43. 8.8 Otsuka
  44. 8.8.1 Otsuka Company Information
  45. 8.8.2 Otsuka Business Overview
  46. 8.8.3 Otsuka Vitamin K Antagonists (VKA) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Otsuka Vitamin K Antagonists (VKA) Product Portfolio
  48. 8.8.5 Otsuka Recent Developments
  49. 8.9 Genentech (Roche)
  50. 8.9.1 Genentech (Roche) Company Information
  51. 8.9.2 Genentech (Roche) Business Overview
  52. 8.9.3 Genentech (Roche) Vitamin K Antagonists (VKA) Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Genentech (Roche) Vitamin K Antagonists (VKA) Product Portfolio
  54. 8.9.5 Genentech (Roche) Recent Developments
  55. 8.10 Daiichi Sankyo
  56. 8.10.1 Daiichi Sankyo Company Information
  57. 8.10.2 Daiichi Sankyo Business Overview
  58. 8.10.3 Daiichi Sankyo Vitamin K Antagonists (VKA) Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Daiichi Sankyo Vitamin K Antagonists (VKA) Product Portfolio
  60. 8.10.5 Daiichi Sankyo Recent Developments
  61. 8.11 Bristol-Myers Squibb
  62. 8.11.1 Bristol-Myers Squibb Company Information
  63. 8.11.2 Bristol-Myers Squibb Business Overview
  64. 8.11.3 Bristol-Myers Squibb Vitamin K Antagonists (VKA) Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Bristol-Myers Squibb Vitamin K Antagonists (VKA) Product Portfolio
  66. 8.11.5 Bristol-Myers Squibb Recent Developments
  67. 8.12 Boehringer Ingelheim
  68. 8.12.1 Boehringer Ingelheim Company Information
  69. 8.12.2 Boehringer Ingelheim Business Overview
  70. 8.12.3 Boehringer Ingelheim Vitamin K Antagonists (VKA) Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Boehringer Ingelheim Vitamin K Antagonists (VKA) Product Portfolio
  72. 8.12.5 Boehringer Ingelheim Recent Developments
  73. 8.13 Aspen
  74. 8.13.1 Aspen Company Information
  75. 8.13.2 Aspen Business Overview
  76. 8.13.3 Aspen Vitamin K Antagonists (VKA) Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Aspen Vitamin K Antagonists (VKA) Product Portfolio
  78. 8.13.5 Aspen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vitamin K Antagonists (VKA) Value Chain Analysis
  2. 9.1.1 Vitamin K Antagonists (VKA) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vitamin K Antagonists (VKA) Sales Mode & Process
  6. 9.2 Vitamin K Antagonists (VKA) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vitamin K Antagonists (VKA) Distributors
  9. 9.2.3 Vitamin K Antagonists (VKA) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst